Isoray To Announce First Quarter Fiscal 2023 Financial Results on November 10, 2022

The grant from the Medical Research Council (MRC) of the United Kingdom (part of UK Innovation and Research; UKRI) is supporting preclinical in vitro and in vivo studies of [212Pb]VMT-𝛼-NET for neuroendocrine tumors (NETs)

Funds from the award are directed to Perspective Therapeutics’ collaborator Dr. Samantha Terry PhD, an expert in radiobiology at King’s College London.

Conference Call is Thursday, November 10, 2022 at 4:30 p.m. ET/1:30 p.m. PT

RICHLAND, WASHINGTON – October 31, 2022 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that it will host a conference call to discuss its financial results for the first quarter fiscal 2023 ended September 30, 2022 on Thursday, November 10, 2022, at 4:30 p.m. Eastern Time. The Company will issue a press release announcing its financial results for the first quarter fiscal year 2023 after the close of the U.S. stock markets on November 10, 2022.

To listen to the conference call, please dial (877) 545-0320. For callers outside the U.S., please dial (973) 528-0002.

The conference call will be simultaneously webcast and can be accessed at The webcast will be available until February 10, 2023 following the conference call.


Investor Relations: Mark Levin (501) 255-1910
Media and Public Relations: Sharon Schultz (302) 539-3747

About Isoray
Isoray, Inc. is a medical technology company pioneering advanced treatment applications and devices to deliver targeted internal radiation treatments for cancers throughout the body. Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting Follow us on LinkedIn and Twitter.

Scroll to top